Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.K&L chooses OpenClinica Enterprise clinical trial software
K&L, which provides end-to-end services for all types of clinical studies, said it is planning to expand its capabilities in the US, Asia and the Pacific region, especially
K&L, which provides end-to-end services for all types of clinical studies, said it is planning to expand its capabilities in the US, Asia and the Pacific region, especially
Prior to joining the company, Adams served at Auxilium Pharmaceuticals as chief executive officer and president and at Neurologix as chairman and chief executive officer. Adams also worked
According to the deal, Cellmid will receive initial fee besides additional payment if Fujikura decides on exercising its license option. Upon any future sales of midkine diagnostic products
The patent entitled, ‘Abuse-Deterrent Drug Formulation’, covers Oxycodone DETERx (COL-003) product which utilizes the company’s proprietary DETERx drug delivery technology. Currently in the final stage of clinical development,
The application covers a drug delivery system based on the company’s Smart Surface technology, which electronically or manually controls the dispensing of a fluid on a nano-structured surface.
Mesoblast will supply MPCs manufactured at Singapore manufacturing facility of its contract manufacturer, Lonza, besides at its US facility. Mesoblast chief executive Professor Silviu Itescu said, "Having multiple
The progression of the compound into pre-clinical development has triggered a milestone payment to Evotec from Ono, as per the deal signed between the companies in March 2008.
As per the deal, RQx will earn an up-front payment in addition to research and development milestone payments worth $111m. RQx CEO and venture partner at Avalon Venture
The collaboration will focus on developing small-molecule therapies directed to select new targets to treat autoimmune diseases. Lycera president and chief executive officer Kathleen Metters said, "Lycera’s proven
Sobi gained distribution rights in Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal, and Luxembourg. The distribution is expected to